Discover Vicebio's molecular clamp technology as it completes a $100 million series B round for its bivalent vaccine against ...
The former head of vaccine R&D at GSK has pulled together $100 million for a London-based biotech working on respiratory ...
The company’s technology, which enables it to target viral proteins in their “prefusion” shape and skip a manufacturing step, could lead to vaccines that are more potent and easier to produce, said ...